# ITIL-306 in Advanced Solid Tumors

> **NCT05397093** · PHASE1 · TERMINATED · sponsor: **Instil Bio** · enrollment: 1 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** ITIL-306

## Key facts

- **NCT ID:** NCT05397093
- **Lead sponsor:** Instil Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-24
- **Primary completion:** 2023-10-10
- **Final completion:** 2026-03-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was terminated early due to discontinuation of development of the investigational program
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397093, "ITIL-306 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05397093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*